Background. IPA causes high morbidity and mortality in immunocompromised patients, but diagnosis remains challenging. A newly formatted AspLFD targets specific Aspergillus antigen JF5, but reported results for this test are variable. We evaluated the performance characteristics of this new AspLFD in BAL fluid of patients with IPA.
Background. Empiric antifungal treatment is recommended in patients with suspected candidemia given the 20-40% associated mortality. T2Candida Panel (T2) is approved for the rapid detection directly on a blood sample of candidemia caused by
C. albicans/C. tropicalis (CA/CT), C. parapsilosis (CP), C. glabrata/C. krusei (CG/CK).
Our hospital implemented a candidemia management protocol utilizing T2 to identify candidemia in high-risk patients. We examine the potential for antifungal stewardship by analyzing T2 species-specific result-based antifungal de-escalation.
Methods. Retrospective analyses were conducted on 70 T2-positive patients identified in 2016-2017 at our hospital. The primary endpoint is time to de-escalation from echinocandin to fluconazole based on T2 species identified. Secondary endpoints included time to T2 positivity, and identification of risk factors for mortality. Univariate logistic regression was used to determine association between risk factors and mortality. Multivariate logistic regression models were created using forward selection to model the odds of mortality. Time to de-escalation of echinocandins was modeled using Kaplan-Meier estimators.
Results. In T2-positive results for CA/CT or CP, 50% of patients were de-escalated to fluconazole therapy within 96 hours. In T2-positive result for CG/CK, 50% of patients were de-escalated in 20 days (figure). The turnaround time (TAT) for T2 6 hours (3-12 hours). Overall mortality was 47% in the T2-positive cohort and was unchanged over the study period. Univariate analysis showed statistically significant associations between mortality and sepsis diagnosis, hypotension, abnormal WBC count, and tachycardia (P < 0.05). Multivariate analysis showed tachycardia, age, and presence of prosthetic devices, taken together, fit the best model to predict odds of mortality (P < 0.05).
Conclusion. T2 proved useful in promoting de-escalation of echinocandin to fluconazole therapy in patients with fluconazole-susceptible Candida species. The rapid TAT of T2 promotes timely de-escalation of enchinocandins. Overall mortality in patients with suspected candidemia remains unaffected despite rapid diagnostics and early empiric antifungal therapy. Background. Early diagnosis of IPA is challenging and has a direct impact on mortality. Several diagnostic modalities have been developed with variable performance. AspID is a new multiplex Aspergillus qRT-PCR assay and AspLFD is a rapid test that targets the Aspergillus specific antigen JF5; both tests were developed by OLM Diagnostics. We evaluated the performance characteristics of AspID used alone and in combination with AspLFD on BAL fluid of patients at high risk for IPA.
Disclosures
Methods. Samples had been prospectively banked in our BAL repository. Fortytwo samples, 14 from patients with proven/probable IPA by EORTC/MSG criteria and 28 from control patients without IPA, were tested with AspID and AspLFD. For AspID, DNA extraction and qRT-PCR were performed per manufacturer instructions. For AspLFD, 100 μL of sample was applied to the device. AspID and AspLFD results were each read by three different blinded observers. Only patient with a valid result for both tests were included in the analysis. Sensitivity, specificity, and accuracy of AspID alone and in combination with AspLFD were calculated.
Results. Of the 42 samples, 22 were excluded because the AspID internal extraction control showed the assay to be invalid and one sample was excluded because the AspLFD internal control line was not visible. Thus, 19 patients were analyzed, eight with IPA and 11 without IPA. Among eight IPA cases, seven were positive by AspID and one was negative; two tested positive by AspLFD and six were negative. Of the 11 control patients without IPA, four were positive by AspID and seven were negative; all 11 were negative by AspLFD. AspID sensitivity was significantly higher than that of AspLFD (87.5% vs. 25%, P = .0001), but specificity of AspLFD was superior to that of AspID (100% vs. 64%, P = 0.049). Accuracy was 74% for AspID and 68% for AspLFD. When deciding whether doing both tests was beneficial for diagnosis, union analysis showed the sensitivity to be 87.5% and the specificity to be 64%. Accuracy was not improved and remained at 74%. Background. Timely empiric antifungal therapy is essential in the management of candidemia but must be weighed with the risks of overuse. The purpose of this study was to compare preemptive antifungal therapy and outcomes following a negative T2MR or BDG test result among ICU patients.
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Conclusion. AspID had higher sensitivity than AspLFD and AspLFD had higher specificity than AspID. Using both tests in combination did not improve the ability to diagnose IPA in patients with classic risk factors. Disclosures. All authors: No reported disclosures.
T2-Candida (T2MR) vs. Β-D-Glucan (BDG) for Preemptive Antifungal
Methods. IRB-approved, quasi-experiment in a four hospital system, May 2014-October 2017. T2MR implemented November 2015. Inclusion: preemptive anidulafungin (AFG), negative blood culture(s) and either a negative BDG by system guideline interpretation or T2MR. Exclusions: transplant, neutropenia, or another documented indication for antifungals. Primary endpoint: days of preemptive AFG. Secondary outcomes: ICU and hospital length of stay, incidence of invasive candidiaisis after discontinuation of preemptive therapy, reinitiation of antifungal therapy in the index admission, and inpatient mortality. Early discontinuation defined as single dose only.
Results. A total of 179 patients included: BDG n = 79, T2MR n = 100. Median age: BDG 63 (50, 71); T2MR 59 (50, 70). Baseline SOFA score: 8 (6,11) BDG; 12 (8,15) T2MR. Candida score ≥ 3: 43 and 41%, respectively. Preemptive AFG: 2 (1,5) days BDG and 1 (1,2) days T2MR (P < 0.001). Subsequent proven candidemia: 2 (2.5%) BDG; 1 (1%) T2MR. Antifungal reinitiated: 13 (17%) BDG; 12 (12%) T2MR. Mortality: 35 (44%) BDG, 59 (59%) T2MR, P = 0.07. AFG was discontinued early in 91 (51%) patients. T2MR was the only characteristic associated with early D/C (Table 1) .
Conclusion. T2MR testing facilitates use of early preemptive echinocandin therapy in ICU patients and minimizes unnecessary prolonged therapy when compared with use of BDG. October 6, 2018: 12:30 PM Background. Β-D glucan (BDG) assay is a noninvasive test for presumptive diagnosis of invasive fungal infections (IFI). The utility of BDG assay and cut off values for positive, intermediate or negative test has been primarily studied in patients with hematological malignancies. However, the role of BDG in solid-organ transplant (SOT) recipients is not well described. The aim of this study was to evaluate the utility of serum BDG assay for IFI diagnosis in SOT recipients.
Utility of Serum Β-D Glucan Assay for Diagnosis of Invasive Fungal Infections in Solid Organ Transplant Recipients
Methods. We retrospectively reviewed 200 patients who underwent SOT at Mayo Clinic and had BDG assay done for suspected IFI between January 1, 2013 and April 1, 2018. IFI cases were classified as proven, probable, and possible using EORTC/MSG criteria. Cases where BDG assay was used for treatment response follow-up or where results were inconclusive were excluded. BDG assay was performed at Viracor Eurofins Clinical Diagnostics lab. For the purpose of this study, a value of ≥80 pg/mL was considered positive and <80 pg/mL (intermediate or negative) was considered negative.
Results. A total of 117 tests from 104 patients met study inclusion criteria. The mean patient age was 56.2 years and 71 (60.7%) were male. Type of SOT included kidney (64), liver (30), heart (26), pancreas (6), and lung (6). BDG assay was positive in seven out of 10 invasive aspergillosis, two out of 3 invasive candidiasis, three out of four pulmonary coccidioidomycosis, and one Pneumocystis jirovecii pneumonia (Table 1) . Overall, BDG assay was positive in 72.7% of cases (16/22) where a BDG containing organism was the etiology of invasive infection (sensitivity). It was false-positive in seven cases where a BDG containing organism was not identified. Overall specificity of the assay was 92.6% (Table 2) .
Conclusion. BDG assay is a useful adjunctive diagnostic aid for distinguishing IFI cases from those without IFI in SOT recipients. 
